AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03547167 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
Study NCT03547167 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study NCT03547167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study NCT01446718 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gardasil vaccine
Description: 0.5ml of intramuscular vaccine in three doses
Study NCT02302157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AST-OPC1
Description: One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent
Study NCT02076594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Powder for solution for infusion
Study NCT02076594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Solution for infusion
Study NCT02076594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Powder for solution for infusion
Study NCT02042456 — intervention group
Intervention type: DEVICE
Intervention: Full Field Digital Mammography
Study NCT01808573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Study NCT01808573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study NCT01702454 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix Quadrivalent
Description: 1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
Study NCT02228551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Augmented renal clearance Point prevalence study
Description: An 8-hour urine collection was carried out to determine the CrCl8h. Participants were asked to empty the bladder at the start of the collection. From then, patients were asked to collect urine in a recipient during the following 8 hours. If an indwelling transurethral or suprapubic urinary catheter was in situ, the collection bag was emptied at the start of the collection. After 8 hours, total urinary volumes (Uv8h) were measured with a measuring cup and urinary creatinine concentrations were determined by laboratory analysis. Midterm serum creatinine samples were obtained at 4 hours after the start of the urinary collection. Based on these values, CrCl8h was calculated according to the standard formulas and normalized to a body surface area (BSA) of 1.73m².
Study NCT02390401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure
Description: Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.
Study NCT02390401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sterile dressing
Description: Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
Study NCT04762797 — intervention group
Intervention type: OTHER
Intervention: Non
Description: This is a retrospective study, without intervention.
Study NCT03596528 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lung biopsy
Description: Each patient will be brought to the operating room and will undergo cryobiopsy and surgical biopsy of the lung sequentially in the same surgical stage.
Study NCT00994292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT00994292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01389544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 200 mg daily (100 mg q12h) orally, Days 1-10
Study NCT01389544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone
Description: stable maintenance therapy: 20-120 mg daily single oral morning dose
Study NCT01389544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 200 mg daily (100 mg q12h) orally, Days 1-10
Study NCT00851812 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Standard care monitoring
Study NCT02076594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Film coated tablets
Study NCT03650465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Description: Cognitive-behavioral therapy (CBT)
Study NCT01332188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 0%
Description: 1 drop in each eye at 3 separate times during a 21 day period
Study NCT01502150 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
Study NCT01502150 — intervention group
Intervention type: OTHER
Intervention: Dose Distribution Data Collection
Description: Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
Study NCT03411564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filming Together to See Ourselves in a New 'Present'
Description: PHASE 0. PRIOR TRAINING 1) Promoting protective assets related to violence together. 10-hour training session with 10-15 secondary school teachers; 2) Identifying our own protective assets against violence. This training activity will be addressed to targeted students. The activity will be carried out in four sessions of 1 hour in duration.~PHASE 1.PRE-PRODUCTION. 1) Participant activity on building story arguments; and 2) Construction of a technical and literary guide to the video capsules.~PHASE 2: PRODUCTION.- 1) Rehearsal of the script developed by each group; 2) Preparation and selection of environment, wardrobe and characterization of the roles and, 3) Filming of the video capsules.~PHASE 3: POST-PRODUCTION.- This phase consists of putting together the short film using the various video capsules.~PHASE 4: DISSEMINATION. A short film exhibition to provide a space where participants can present their video capsules and briefly explain the production process.
Study NCT03888677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU, epirubicin and cyclophosphamide
Description: Tailored dose escalation of epirubicin and cyclophosphamide.
Study NCT03888677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, epirubicin and cyclophosphamide
Description: Tailored dose escalation of epirubicin and cyclophosphamide.
Study NCT02251717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study NCT03905317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
Study NCT03905317 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest radiation
Description: The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.
Study NCT00851812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive walking and resistance exercise treatment
Description: Home-based exercise : Progressive walking and resistance program
Study NCT03905317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy
Description: weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
Study NCT02262442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enk Fiberoptic Atomizer
Description: Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy
Study NCT02262442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bronchoscope
Description: Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
Study NCT01545232 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 1:1:1 Blood Transfusion Ratio
Description: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
Study NCT01545232 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 1:1:2 Blood Transfusion Ratio
Description: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
Study NCT03069287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benjamin Rose Institute (BRI) Care Consultation™ Program
Description: The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
Study NCT02071186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality training
Description: Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.~To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis.
Study NCT02071186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Remediation
Description: Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.
Study NCT02071186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Study NCT01377948 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACT with RAGE-Control
Description: This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
Study NCT02036736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative anesthetic strategy by Propofol
Description: 1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~* Sufentanil (0.15 mg / kg intravenously (IV))~* Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade
Study NCT02036736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative anesthetic strategy by Desflurane
Description: 2- Arm Desflurane Desflurane induction (2-3 mg / kg)~* Sufentanil (0.15 mg / kg IV)~* Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade
Study NCT01499550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: humidified transnasal insufflation (TNI20oxy)
Description: The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
Study NCT01499550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: overnight oxygen treatment with individual flow rate
Description: The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
Study NCT04466254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPGJ602
Description: Q2W/QW iv
Study NCT00378599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of (a) pegylated interferon alfa-2b and (b) rebetol
Description: 1. Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks
Study NCT02462408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior approach
Description: The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
Study NCT02462408 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional approach
Description: The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
Study NCT00489736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronedarone (SR33589)
Description: oral administration
Study NCT00489736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiodarone
Description: oral administration
Study NCT04021524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide 10% Bar
Description: Patients will wash with Benzoyl Peroxide 10% Bar
Study NCT04021524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Patients will wash with Chlorhexidine Gluconate
Study NCT04172168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rupture
Description: Left ventricular free-wall ruptrue after AMI
Study NCT04466254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: QW iv
Study NCT03109301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib (AZD6244 hyd sulfate) 50mg/dose
Description: Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
Study NCT03109301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib (AZD6244 hyd sulfate) 25mg/m2
Description: Selumetinib will be administered at a starting dose of 25 mg/m2/dose in children \< 18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
Study NCT04493281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Oral suspension
Study NCT04493281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCI-186
Description: Intravenous formulation
Study NCT02707393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: infusion
Study NCT02707393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: infusion
Study NCT02707393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: infusion
Study NCT02707393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: infusion
Study NCT02707393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: infusion, orally if possible
Study NCT02707393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: infusion
Study NCT02707393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow or peripheral blood stem cells
Description: infusion
Study NCT04526873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postcard
Description: Mailed
Study NCT03733691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: 3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles
Study NCT04526873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call
Description: May be automated or by human
Study NCT04526873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humor/Salience
Description: Funny cartoon + health risk examples
Study NCT03733691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Same dose as in the front-line treatment in the last treatment cycle, taken orally, on days 1-28 of a 28-day cycle.
Study NCT00934154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg/day continuously for 12 months
Study NCT00934154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan+Prednisolone
Description: Melphalan 2 mg, Prednisolone 16 mg
Study NCT04526873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Information about video visit
Study NCT00934154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan+Prednisolone
Description: Melphalan 2 mg, Prednisolone 16 mg
Study NCT02670954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, tramadol and flurbiprofen
Study NCT02670954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol and flurbiprofen
Study NCT03279523 — intervention group
Intervention type: DRUG
Intervention: F 18 T807
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study NCT04447599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photography of conjunctival vessels
Description: patient will have photo of their bulbar conjunctival of each eye and photography of fundus without dilatation
Study NCT01307202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
Study NCT01307202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will match the the gabapentin pill and will be given orally.
Study NCT01678352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Lysate Vaccine
Description: Cohort 1 Cohort 2 Cohort 3
Study NCT02305108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascial manipulation
Description: Recruited patients in study's group will be treated with the standard treatment and fascial manipulation.~Specific points of fascial tissue will be treated with a deep friction to improve elasticity.~The number of point treated will be refered to a specific evaluation for each patient.~Fascial manipulation provide 3 session treatment (one treatment for week).
Study NCT02305108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.~After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training.
Study NCT02305108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.~After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training.